Halberd Corp. Archives - Page 2 of 6

Aug 23 2021

Halberd Files Provisional Patent Application – Furthering Efforts on Alzheimer’s Disease

By Admin|2021-08-22T21:05:51-04:00August 23rd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 23, 2021 – Halberd Corp. (OTC PINK: "HALB") announced filing a U. S. joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.” The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU). The provisional patent application covers technology developed ...

Jul 22 2021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

By Admin|2021-07-21T19:48:45-04:00July 22nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau. Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU). At YSU, Dr. William G. Sturrus, ...

Jun 30 2021

Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process

By Admin|2021-06-29T23:00:53-04:00June 30th, 2021|Featured, Investor News, News|0 Comments

Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies. This simplified method for the removal of disease-causing antigen(s) utilizes more conventional ...

Jun 21 2021

Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

By Admin|2021-06-20T21:56:56-04:00June 21st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to ...

Jun 16 2021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

By Admin|2021-06-15T21:04:24-04:00June 16th, 2021|Featured, Investor News, News|0 Comments

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal ...

Jun 9 2021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

By Admin|2021-06-08T21:47:47-04:00June 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...

May 25 2021

Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody

By Admin|2021-05-24T21:12:58-04:00May 25th, 2021|Featured, Investor News, News|0 Comments

Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody. This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...

May 19 2021

“MarketWatch” Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19

By Admin|2021-05-18T22:02:25-04:00May 19th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") was featured in a recent MarketWatch article, “New Approaches to Covid-19 Treatment Enter the Picture,” along with six other notable biotechnology companies. As stated in the article, “The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE:PFE), BioNTech ...

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By Admin|2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

May 13 2021

Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease

By Admin|2021-05-12T20:19:30-04:00May 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 13, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease. This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications. The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of ...

Previous 123 Next